2021 SGO Virtual Meeting Sunday March 21, 2021

I am happy to share with you Tweets that cover the work presented during the last full day session of SGO was on Sunday, March 21, 2021.

One session, Time to Return to the Drawing Board, reported clinical trial results that did not meet their aims. Understanding where a drug or treatment may have failed to provide the results expected is as important as those trials that meet aims.

 Atezolizumab

#SGOMtg Association of BRCA1/2, HRD, and PD-L1 with clinical outcomes in patients receiving atezolizumab vs placebo combined with carbo, paclitaxel, and bev for newly dx
#gyncsm
Landen pic.twitter.com/qIc5j31bHD

— Dee Sparacio (@womenofteal) March 21, 2021

Falretuzumab

#SGOMtg
Phase 2 study to assess the efficacy/safety of farletuzumab in combo with carboplatin plus paclitaxel or carbo plus pegylated liposomal doxorubicin in women w/ low CA125 ( less than 3xs upper level
T. Herzog
Efficacy - no difference
PFS no difference #gyncsm pic.twitter.com/Xq98SqtXS4

— Dee Sparacio (@womenofteal) March 21, 2021

Dr. Herzog presents negative study of addition of farletuzumab (folate receptor alpha mAB) to chemo in pts with platinum sensitive #ovariancancer with CA-125 less than 3x ULN. No improvement in PFS or OS with the addition of the novel agent. #SGOMtg #gyncsm pic.twitter.com/dJq7g8fqSy

— Shannon Westin (@ShannonWestin) March 21, 2021

 

Durvalumab and Trememlimumab

#SGOMtg
Phase II Durvalumab (anti-PDL1)& Tremelimumab (anti-CTLA4) Administered in Combo versus Sequentially for the Treatment of Recurrent PR HGSOC
No diff between arms in PFS
Clear cell histology should be examined
E. Hinchcliff #gyncsm pic.twitter.com/ky6BBP72ZG

— Dee Sparacio (@womenofteal) March 21, 2021

phase II durvalumab and tremelimumab with front-line neoadjuvant chemo in patients with advanced-stage epithelial ovarian cancer
J. Lee
Manageable AEs
NACT increase in CD8T, PDL1 expression#gyncsm pic.twitter.com/iOhbYrcnys

— Dee Sparacio (@womenofteal) March 21, 2021

Additional sessions of interest.

Barriers to Quality of Care - Poster 

Significant barriers and challenges to receipt of quality care in #ovariancancer were identified. How do we raise the bar in access and treatment in this disease? #gyncsm #SGOMtg #sgo2021 pic.twitter.com/t2FJ3PW5Ew

— Sarah Temkin (@temkins) March 22, 2021

Uterine lavage and early detection

GynOnc Fellow Talayeh Ghezelayagh wowed the audience with her featured poster on uterine lavage, a novel early detection method for ovarian cancer. Great Q&A demonstrated her comfort with this high tech genomic study- great mentorship Dr. Rosana Risques.@UWMedicine @UWashOBGYN pic.twitter.com/SR23kC8f0H

— liz swisher (@SwisherLiz) March 21, 2021

Post operative opiods use model 

@BrittDavidsonmd: Development and validation of the Gynecologic Oncology Predictor of Postoperative opioid use (go-pop) model at #SGOMtg I love GO-POP's potential to provide ALL patients with the amount of pain control that they need #SGOPatAdv pic.twitter.com/SpYhoRxIEU

— Annie Ellis (@Stigetta) March 21, 2021

Neuropathy and genetic variants 

Lauren Thomaier presents Genetic variants predictive of chemotherapy-induced peripheral neuropathy symptoms in gynecologic cancer survivors at #SGOMtg Fantastic work to identify patients most at risk of CIPN! Very important! #SGOPatAdv #GYNcsm pic.twitter.com/GCeSoRXWn3

— Annie Ellis (@Stigetta) March 21, 2021

Gross resection and OS / NACT

Great study by @NiteckiRoni showing complete gross resection still remains integral to improving OS and ability to get R0 should inform surgical timing, not number of NACT cycles. @MDAndersonNews @SGO_org #SGO2021 #SGOMtg @RauhHainMD pic.twitter.com/uQAIl0KygU

— Jeffrey How (@jahow514) March 21, 2021

#SGOmtg Surgical Debulking improves survival in high-grade serous carcinoma regardless of platinum sensitivity
N. Cardillo #gyncsm
Retrospective
Optimal surgery is an independent predictor of survival. pic.twitter.com/BpYuZGX4bK

— Dee Sparacio (@womenofteal) March 21, 2021

Partial response or stable disease after neoadjuvant chemotherapy for advanced ovarian cancer-time for surgery or more chemotherapy?
R. Nitecki
Retrospective study , Phys choice more chemo or surgery 2013-2019
residual disease drives survival#SGOMtg #gyncsm pic.twitter.com/VRh51mdXGm

— Dee Sparacio (@womenofteal) March 21, 2021

Vulvar Cancer Studies 

The accuracy of intraoperative frozen section examination of sentinel lymph nodes in squamous cell cancer of the vulva
B. Swift
snl = sentinel lymph nodes #SGOMtg #gyncsm pic.twitter.com/1ddaquo643

— Dee Sparacio (@womenofteal) March 21, 2021

Volume-outcome relationship in vulvar cancer treatment: A Japanese Gynecologic Oncology Group Study

S. Nishio#SGOMtg#gyncsm
>1000 women
no association of hospital volume relationship and PFS pic.twitter.com/0fsEp7Lfnk

— Dee Sparacio (@womenofteal) March 21, 2021

#SGOMtg Vulvar Cancer Research
Pembrolizumab for vulvar squamous cell carcinoma: results from the phase 2 KEYNOTE-158 study
R. Shapira Frommer
Responses independent of PDL-1 status. #gyncsm pic.twitter.com/IJj1eLjdpg

— Dee Sparacio (@womenofteal) March 21, 2021

Endometrial cancer 

Cediranib and Olaparib NRG GY012

Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combination of Cediranib/Olaparib in Women with Recurrent, Persistent or Metastatic Endometrial Cancer
BJ Rimel NRG GY012 study #SGOMtg
#gyncsm
Did not m pic.twitter.com/YxDK8S565f

— Dee Sparacio (@womenofteal) March 21, 2021

IUD

#SGOMtg
Complete pathological response following levonorgestrel intrauterine device in clinically stage 1 endometrial adenocarcinoma: @AndreasObermair 165 patients
Weight loss may help response. #gyncsm pic.twitter.com/zfh3cc9WiN

— Dee Sparacio (@womenofteal) March 21, 2021

 Enzalutamide

#SGOMtg ENPAC: Phase II trial with safety lead of enzalutamide in combination with paclitaxel and carbofor adv or recurrent endometrioid endometrial adenocarcinoma
Westin #gyncsm health moderator
Andogen receptor expressed in endometroid OC , 35 patients
tolerable. pic.twitter.com/r8ZS9Nfijc

— Dee Sparacio (@womenofteal) March 21, 2021

Here are some articles from various sources that go more into depth about studies discussed at the meeting. 

Medscape article on hormone IUD and endometrial cancer https://www.medpagetoday.com/meetingcoverage/sgo/91740

Vulvar cancer patients with sentinel node micrometastases, radiation therapy (RT) to the groin after local excision led to extremely low rates of recurrence, a phase II trial suggested https://www.medpagetoday.com/meetingcoverage/sgo/86603 

ABV-500 small molecule in OC https://www.medpagetoday.com/meetingcoverage/sgo/91739

 

Thank you so Eisai for supporting patient advocates at the annual meeting . 

Thank you SGO leadership for making us feel welcome and for all the gyn oncs who answered our questions.  

Dee

Every Day is a Blessing!

2021 SGO Virtual Annual Meeting Saturday March 20

Here are highlights from the Virtual #SGOmtg sessions I attended on Saturday March 20, 2021. 

The morning began with a wonderful get-together for Patient Advocates at a 9am session. I am so glad to see patient advocates play a role in so many aspects of the SGO organization.

 In real time, I shared information on Twitter( @womenofteal) about the sessions I attended using the #gyncsm and #SGOmtg hashtags

 Surgery:

Scientific Plenary II: Cutting Edge - Advancing Surgical Innovation -If Looks Could Kill: Morphologic Subtypes of High-Grade Serous Ovarian Cancer
Dr Katelyn Handley- Looking at morphology and molecular difference in OC #SGOMtg #gyncsm #SGOPatAdv pic.twitter.com/LavQt2RBLp

— Dee Sparacio (@womenofteal) March 20, 2021

Higher Surgical Volume is Associated with Better Outcomes for Frail Patients Undergoing Surgery for Ovarian Cancer- M. Nakhla #SGOMtg #gyncsm pic.twitter.com/3ZU7q8KZ0R

— Dee Sparacio (@womenofteal) March 20, 2021

MEDSCAPE shared this article on MIS and interval debulking surgery. https://www.medpagetoday.com/meetingcoverage/sgo/91738

Equity 

Education Forum V: Eradicating Racism and Discrimination in Medicine Thank you Dr Latimore. #SGOMtg #gyncsm
Have you ever taken a test to measure your implicit bias? I have. Results were not what I expected. We can do better. "See people as an individual." pic.twitter.com/bCEYQ1IDiY

— Dee Sparacio (@womenofteal) March 20, 2021

Education Forum V: Eradicating Racism and Discrimination in Medicine #SGOMtg #gyncsm
Dr Marsh
"We have to see it."
"Honesty is more important than fear"
We need to do this now. pic.twitter.com/48BS8u4I2B

— Dee Sparacio (@womenofteal) March 20, 2021

How to address our own biases? We needs to address our own biases while addressing bigger picture in our society! #SGOMtg #sgo2021 @SGO_org @somedocs #MedTwitter #obgyntwitter #gyninfluencer pic.twitter.com/Kk20tx51YD

— Payam Katebi Kashi, MD, PhD (@PayamKashiMD) March 20, 2021

PAOLA-1 Olaparib plus Bev

Seminal Abstract Session: Taking a Deeper Dive into Practice-Changing Trials
HR repair mutation gene panels (excluding BRCA) are not predictive of maintenance olaparib plus bevacizumab efficacy in the first-line PAOLA-1/ENGOT-ov25 trial
E. Pujade-Lauraine#SGOMtg #gyncsm pic.twitter.com/sEUkrDBAzJ

— Dee Sparacio (@womenofteal) March 20, 2021

Tumor infiltrating lymphocytes

Great job @AmirJazaeri - impressive response of #cervicalcancer to TIL therapy with LN-145! Responses were durable and median duration of response was not reached. #SGOMtg #gyncsm pic.twitter.com/QDaLusnqv3

— Shannon Westin (@ShannonWestin) March 20, 2021

Great job @AmirJazaeri - impressive response of #cervicalcancer to TIL therapy with LN-145! Responses were durable and median duration of response was not reached. #SGOMtg #gyncsm pic.twitter.com/QDaLusnqv3

— Shannon Westin (@ShannonWestin) March 20, 2021

Keynote 158 Cervical Cancer

Updated data from the KEYNOTE-158 study of pembrolizumab in recurrent #cervicalcancer - response rate of 17% in pts with PD-L1 positive tumors. Median time to response was 2 months- fast acting! Med duration of response not reached... #SGOMtg #gyncsm pic.twitter.com/ut0EinNBvy

— Shannon Westin (@ShannonWestin) March 20, 2021

 

Scientific Plenary III: Seminal Abstract Session: Taking a Deeper Dive into Practice-Changing Trials
Pembrolizumab treatment of advanced cervical cancer: updated results from the phase 2 KEYNOTE-158 study
H. Chung#SGOmtg #gyncsm pic.twitter.com/qdBegPgXfZ

— Dee Sparacio (@womenofteal) March 20, 2021

 ENGOT-OV 16/ NOVA  niraparib

Seminal Abstract Session: Taking a Deeper Dive into Practice-Changing Trials
Dr Matulonis
ENGOT-OV16/NOVA phase III trial of niraparib in recurrent ovarian #SGOmtg #gyncsm pic.twitter.com/wwd9DwuTho

— Dee Sparacio (@womenofteal) March 20, 2021

PARP Inhibitor duration of follow-up

Seminal Abstract Session: Taking a Deeper Dive into Practice-Changing Trials Bradley
Seminal Abstract Session: Taking a Deeper Dive into Practice-Changing Trials
Longest duration of follow -up of a PARP inhibitor in trials to date. #SGOmtg #gyncsm pic.twitter.com/hFNBwgsZ5K

— Dee Sparacio (@womenofteal) March 20, 2021

Cervical Cancer Radiation study

#SGOmtg
Translational Research 2021:
Genomic profiling of adv cervical cancer to predict response to PD-1 inhibitor combination therapy: a secondary analysis of the CLAP trial #gyncsm
C. Lan
predictive Biomarker research for cervical cancer pic.twitter.com/IuoDprILOi

— Dee Sparacio (@womenofteal) March 20, 2021

Phase III Ran Trial of Postoperative Adjuvant Conventional Radiation (3DCRT) vs Image Guided Intensity Modulated Radiotherapy (IG-IMRT) in Cervical Cancer (PARCER)
S. Chopra
Reduction in diarrhea, #sgomtg#gyncsm pic.twitter.com/iGgp0EEcdF

— Dee Sparacio (@womenofteal) March 20, 2021

Shared Decision Making Tool

Niraparib as Maintenance Therapy- Dr Matalunis https://ascopost.com/videos/sgo-2021-virtual-annual-meeting-on-womens-cancer/ursula-matulonis-on-ovarian-cancer-niraparib-as-maintenance-therapy/

Priority Assessment for Women with Recurrent Ovarian Cancer: A Pilot Study presented by @StephanieVBlank Aids shared-decision making! Feasible with 97% completion! Next steps: Ongoing assessments, electronic version, languages #SGOmtg #SGOPatAdv #GYNcsm pic.twitter.com/hF4ntyzCwk

— Annie Ellis (@Stigetta) March 21, 2021

TY patients 4 insights Priorities Assessment Tool! Prior work https://t.co/O8UAvCtEKC https://t.co/COvGQgQJeN revealed needs-Standardized way 2 individualize tx discussions &capture changes tx goals/priorities along care continuum @MelissaFrey2 @StephanieVBlank #SGOmtg #SGOPatAdv pic.twitter.com/QDhiPDc8vs

— Annie Ellis (@Stigetta) March 21, 2021

Stop by tomorrow for my Sunday highlights.  

Dee

Every Day is a Blessing!

2021 SGO Virtual Annual Meeting - Friday March 19th Highlights

I was happy to be able to attend the virtual SGO Annual Meeting. The meeting started on Friday, March 19 with sessions during the day and evenings over the weekend. The meeting continues with evening sessions through Thursday March 25th.  Interacting with presenters and others in the chat feature of the meeting platform was exceptionally good and helpful.

 In real time, I shared information on Twitter( @womenofteal) about the sessions I attended using the #gyncsm and #SGOmtg hashtags. Below are some tweets of Fridays sessions I found most interesting.

Friday

Nutritional Supplements 

Now Watching: Catching Up to Speed on the Role of Nutritional Supplements in the Management of Gynecologic Cancer Patients w/ Dr Smith #SGOMtg #SGOPatAdv #GYNcsm
Patient use of supplement has increased up to 60%. Wealth of info like below. pic.twitter.com/OM17J62Q01

— Dee Sparacio (@womenofteal) March 19, 2021

Patients: Please talk to your medical team ASAP if you are currently on treatment & taking any of these supplements! #SGOmtg session: Catching Up to Speed on the Role of Nutritional Supplements in the Management of Gynecologic Cancer Patients w/J Smith PharmD #SGOPatAdv #GYNcsm pic.twitter.com/fHW2HP8BtV

— Annie Ellis (@Stigetta) March 19, 2021

Patient physician conversations

#sgomtg Navigating High Stakes Conversations in Gynecologic Oncology great discussion on those difficult discussions using VITALtalk Excellent consideration of patient goals and needs. #gyncsm pic.twitter.com/GHfNnXrXkR

— Dee Sparacio (@womenofteal) March 19, 2021

 PARP  inhibitors 

Listening to PARP Inhibitors: A Practical Approach to Selection and Management :
Karen Lyle, PA-C , Colleen McCormick, MD, MPH
Excellent overview of trial results of PARP use and its current approval for use.
#SgoMtg #gyncsm pic.twitter.com/Ph1IOS13Js

— Dee Sparacio (@womenofteal) March 19, 2021

 

ARIEL 4  Rucaparib vs chemo

Let the Science Begin ! Plenary session
Results of ARIEL 4 Session #SGOMtg
Rucaparib vs Chemo #gyncsm pic.twitter.com/LQlg32e2MC

— Dee Sparacio (@womenofteal) March 19, 2021

KEYNOTE 146  Pembrolizumab - Lenvatinib

Plenary I session
Keynote 146 Len- Pembro vs TPC #SGOMtg #gyncsm pic.twitter.com/LHz759sQgT

— Dee Sparacio (@womenofteal) March 19, 2021

Additional information may be found in the ASCO Post Article https://ascopost.com/news/march-2021/pembrolizumablenvatinib-may-improve-survival-in-advanced-endometrial-cancer/?utm_source=TAP%2DEN%2D032021&utm_medium=email&utm_term=51c356fa5771cf054b74a66e437b4089

Secondary Cytoreductive Surgery

#SGOMtg Ed Forum Surgery:
Secondary Cytoreduction
Son Study- 2nd Cytoreduction surgery ,
1100 procedures in Korea#gyncsm #SGOPatAdv
Discussion below 1/3 pic.twitter.com/9dPzXpx8k6

— Dee Sparacio (@womenofteal) March 19, 2021

2/3 Dr Coleman 2nd Cytoreductive surgery : NO #gyncsm #SGOPatAdv #SGOMtg pic.twitter.com/biMC2Bkd4d

— Dee Sparacio (@womenofteal) March 19, 2021

3/3 Dr Gardner 2nd Cytoreductive surgery YES#gyncsm #SGOPatAdv #SGOMtg pic.twitter.com/7XLXYysKzk

— Dee Sparacio (@womenofteal) March 19, 2021

Endometrial Cancer

Dr. Arend presents exciting data of a DKK1 inhibitor (DKN-01) in #endometrialcancer - biomarker selection seems possible using DKK1 expression, WNT mutation or PIK3CA mutation. Will be exciting to see this move forward! #SGOMtg #gyncsm pic.twitter.com/nz9yDpKyNp

— Shannon Westin (@ShannonWestin) March 19, 2021

Equity in Gyn Cancers

#gyncsm https://t.co/lAWJMI0hIq

— Dee Sparacio (@womenofteal) March 20, 2021

Viewing an On-Demand session-Diversity and Inclusion: Impact of Historical Bias in Gynecologic Oncology #SGOMtg Dr Jeffrey Hines #gyncsm pic.twitter.com/xEnumzoUTB

— Dee Sparacio (@womenofteal) March 20, 2021

ACA and insurance

>1/5 with #gynecologicalcancer #gyncsm have insurance churn, losing/changing #healthinsurance causing dangerous access/coverage gaps. Catastrophic spending in common. Static assessment of insurance gives us an incomplete picture. Great work @BenAlbrightMD @haleyarden1 👏 @SGO_org https://t.co/wLZEFe6EcV

— Fumiko Ladd Chino, MD (@fumikochino) March 21, 2021

Here was a fun activity on the meeting platform - puzzle time! How I wish we were actually in Seattle

 

Fun activity mark the end of the first day of #SGOMtg
Seattle puzzle is complete! pic.twitter.com/f6zNikUojZ

— Dee Sparacio (@womenofteal) March 20, 2021

 

 

Dee

Every Day is a Blessing!